In short
Clinical trials are investigating VANADIUM OXIDE SULFATE as part of patch testing for metal allergy. These studies look at how well the test works and how safe it is in people with allergic contact dermatitis, including eczema. The main goal is to compare test methods and measure agreement between them.
Key points
- Clinical trials of VANADIUM OXIDE SULFATE are studying patch testing for metal allergy in people with allergic contact dermatitis, and in one record, eczema. The research is in Phase 3, which is a later stage of testing. The main goal is to see how well two patch test methods agree with each other. Researchers measure this using agreement scores such as Cohen’s kappa and percent agreement. The trial records show the same study ID, NCT04500834, with one status listed as Withdrawn and another as Authorised.
Trial overview
The available trial records describe a study called Metal Panel Patch Test and identify VANADIUM OXIDE SULFATE as one of the patch test allergens being studied. The study is listed as an interventional trial, which means researchers actively test a patch method rather than only observing people.
The records show the same study ID, NCT04500834, with two status entries: Withdrawn and Authorised. Both records describe a Phase 3 study focused on patch testing and metal allergens.
Who the studies are for
The target conditions are allergic contact dermatitis and, in one record, eczema. These are skin conditions, and allergic contact dermatitis happens when the skin reacts to something it touches.
The trial data do not list detailed age limits, sex limits, or other participation rules. Based on the source, the main population is people being tested for metal-related skin allergy.
What VANADIUM OXIDE SULFATE is being studied for
In these records, VANADIUM OXIDE SULFATE appears as Vanadium Allergen at 1.3% for cutaneous use, meaning it is placed on the skin as part of patch testing. It is studied alongside other metal allergens such as nickel, copper, tin, manganese, zinc, gold, sodium, ammonium, cobalt, and chromium.
The trial is not presented as a treatment study. Instead, it is a diagnostic study, meaning it is trying to see how well the test identifies allergy and how well two test methods perform.
Main outcomes and endpoints
The primary outcome is concordance, which means agreement, between the hydrogel investigational allergen method and the petrolatum reference allergen method. The study measures this using Cohen’s kappa, a statistic that checks agreement beyond chance, and by positive and negative percent agreement.
The brief summary says the objective is to evaluate the diagnostic efficacy and safety of the investigational allergens and the overall safety and performance of the panel device constituent. In simple terms, the researchers want to know whether the test works well and whether it can be used safely in patch testing.
Study phase and status
Both records list the study as Phase 3. Phase 3 studies are later-stage studies that usually focus on how well a method works in a larger group of people.
One record is marked Withdrawn with planned enrollment of 300 people, while the other is marked Authorised with planned enrollment of 395 people. The source does not explain why the status differs, so the records should be read as separate registry entries for the same study ID.
Trial summary
Overall, the clinical trial data for VANADIUM OXIDE SULFATE focus on patch testing in people with allergic contact dermatitis, and in one record, eczema. The study compares two ways of doing patch tests and checks how closely the results match. The main endpoint is agreement between methods, not symptom relief or treatment of disease.
The records provide a clear research focus: diagnostic performance, safety, and practical use of the allergen panel in skin testing.